ASCO Issues Updated Guideline for Stage IV NSCLC Therapy
FDA Issues Partial Clinical Hold on Lorigerlimab Trial in Gynecologic Cancers: The FDA has announced a partial clinical hold on Lorigerlimab trials owing to several severe safety incidents, including a treatment-related fatality.
Refining Management of Immune-Checkpoint Inhibitor Toxicities in Melanoma: This section covers the strategies currently being applied to manage the toxicity associated with the immune-checkpoint inhibitor in melanoma therapy.
FDA Grants Fast Track Designation to SRN-101 for Recurrent High-Grade Glioma: SRN-101 has received Fast Track approval from the FDA. This step marks a significant breakthrough in treatment options for patients suffering from recurrent high-grade glioma.
Novel Small Molecule Shows Early Activity in Pretreated Multiple Myeloma: Positive initial results are emerging from the trials of a novel small molecule aimed at treating patients with pretreated multiple myeloma.
Comparing Quality of Life Outcomes with Protons vs Photons in OPSCC: The latest updates in oropharyngeal cancer treatments reveal interesting comparisons in quality of life outcomes between proton and photon therapies.
